RxDoctor Payments DataLook up a doctor →

Brian Mulherin, MD

Hematology & Oncology · Indianapolis, INNPI 1922034156

Payments from drug & device makers

$2,201,286in general payments, 2019–2025

Across 373 payments — averaging $5901.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2M
  • Apellis Pharmaceuticals, Inc.$97K
  • AbbVie$15K
  • Gilead$10K
  • Incyte Corporation$7K
  • E.r. Squibb & Sons, L.L.C.$5K
  • plus $38K from 54 others
$744in research payments, 2019–2025

Across 3 payments — averaging $247.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$744

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis58$2,027,829
Apellis Pharmaceuticals, Inc.61$96,969
AbbVie8$15,427
Gilead(2 entities)19$10,470
Incyte Corporation10$7,351
E.r. Squibb & Sons, L.L.C.18$5,067
Beigene USA, Inc.4$3,938
Pharmacosmos Therapeutics Inc.11$3,751
Daiichi Sankyo Inc.12$3,563
Swedish Orphan Biovitrum AB1$3,080
Johnson & Johnson(2 entities)13$2,810
AstraZeneca(2 entities)12$2,482
TG Therapeutics, Inc.2$2,330
Vertex6$1,663
Pharmacyclics LLC, An Abbvie Company11$1,535
CTI Biopharma Corp.1$1,438
Amgen11$1,278
Blueprint Medicines Corporation1$1,182
Avyxa Pharma, LLC1$1,000
Geron Corporation2$992
Macrogenics, Inc.1$800
Spectrum Pharmaceuticals Inc.1$750
Sanofi-aventis U.S. LLC4$750
Sanofi6$739
GSK8$611
Fennec Pharmaceuticals, Inc.3$483
Pfizer11$298
ZOLL Medical Corporation1$293
Cardinal Health 110 LLC1$275
Novocure GmbH1$200
Lilly USA, LLC7$194
Athenex Pharmaceutical Division, LLC1$175
Genmab U.S., Inc.4$129
Genentech, Inc.1$127
Merck8$124
Astellas Pharma US Inc4$103
Eisai Inc.4$92
Bristol Myers Squibb4$92
Adaptive Biotechnologies Corporation1$90
Exelixis Inc.4$89
AVEO Pharmaceuticals, Inc.4$81
Puma Biotechnology, Inc.3$67
Bayer3$65
Seagen Inc.2$58
Takeda Pharmaceuticals U.S.A., Inc.2$41
Servier Pharmaceuticals LLC2$38
Genentech USA, Inc.2$37
Tersera Therapeutics LLC1$36
Immunocore Limited2$35
Syndax Pharmaceuticals, Inc.1$27
Coherus Oncology, Inc.1$26
ADC Therapeutics America, Inc.1$24
EMD Serono, Inc.2$22
Jazz Pharmaceuticals Inc.1$20
Epizyme, Inc.1$19
Boehringer Ingelheim1$17
Tempus AI, Inc1$17
Iovance Biotherapeutics, Inc.1$17
Dova Pharmaceuticals1$16
Array Biopharma Inc1$16

How this compares

$2,201,286 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024
$1,657,659
Medicare patients
680
Services billed
55,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Indianapolis

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →